Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease

Meloni, Mario;Figorilli, Michela;Carta, Manolo;Tamburrino, Ludovica;Sanna, Fabrizio;Defazio, Giovanni;Puligheddu, Monica
2022-01-01

Abstract

Altered serotonergic neurotransmission may contribute to the non-motor features commonly associated with Parkinson's disease (PD) such as sleep disorders. The 5-hydroxytryptophan (5-HTP) is the intermediate metabolite of L-tryptophan in the production of serotonin and melatonin. The purpose of this study was to compare the effects of 5-HTP to placebo on REM sleep behavior disorder (RBD) status in patients with PD.
2022
2021
Inglese
26
3
1023
1031
9
Esperti anonimi
scientifica
5-Hydroxytryptophan; Melatonin; Parkinson’s disease; REM sleep behavior disorder; Serotonin
no
Meloni, Mario; Figorilli, Michela; Carta, Manolo; Tamburrino, Ludovica; Cannas, Antonino; Sanna, Fabrizio; Defazio, Giovanni; Puligheddu, Monica ...espandi
1.1 Articolo in rivista
info:eu-repo/semantics/article
1 Contributo su Rivista::1.1 Articolo in rivista
262
8
open
File in questo prodotto:
File Dimensione Formato  
Meloni2021_Article_PreliminaryFindingOfARandomize.pdf

accesso aperto

Tipologia: versione editoriale
Dimensione 818.04 kB
Formato Adobe PDF
818.04 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Questionario e social

Condividi su:
Impostazioni cookie